This company has been marked as potentially delisted and may not be actively trading. ERYTECH Pharma (ERYP) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock ERYP vs. TRML, SANA, TECX, MAZE, TSHA, AUTL, ALLO, PROK, GLUE, and ATYRShould you be buying ERYTECH Pharma stock or one of its competitors? The main competitors of ERYTECH Pharma include Tourmaline Bio (TRML), Sana Biotechnology (SANA), Tectonic Therapeutic (TECX), Maze Therapeutics (MAZE), Taysha Gene Therapies (TSHA), Autolus Therapeutics (AUTL), Allogene Therapeutics (ALLO), ProKidney (PROK), Monte Rosa Therapeutics (GLUE), and Atyr PHARMA (ATYR). These companies are all part of the "biological products, except diagnostic" industry. ERYTECH Pharma vs. Tourmaline Bio Sana Biotechnology Tectonic Therapeutic Maze Therapeutics Taysha Gene Therapies Autolus Therapeutics Allogene Therapeutics ProKidney Monte Rosa Therapeutics Atyr PHARMA Tourmaline Bio (NASDAQ:TRML) and ERYTECH Pharma (NASDAQ:ERYP) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their valuation, earnings, risk, community ranking, dividends, media sentiment, institutional ownership, analyst recommendations and profitability. Do insiders & institutionals believe in TRML or ERYP? 91.9% of Tourmaline Bio shares are owned by institutional investors. Comparatively, 1.1% of ERYTECH Pharma shares are owned by institutional investors. 11.0% of Tourmaline Bio shares are owned by insiders. Comparatively, 1.9% of ERYTECH Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, TRML or ERYP? Tourmaline Bio has a beta of 2.14, meaning that its stock price is 114% more volatile than the S&P 500. Comparatively, ERYTECH Pharma has a beta of 2.69, meaning that its stock price is 169% more volatile than the S&P 500. Which has stronger earnings & valuation, TRML or ERYP? ERYTECH Pharma has higher revenue and earnings than Tourmaline Bio. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTourmaline BioN/AN/A-$42.12M-$2.87-5.68ERYTECH Pharma$32.66M3.24-$240KN/AN/A Does the media favor TRML or ERYP? In the previous week, Tourmaline Bio had 12 more articles in the media than ERYTECH Pharma. MarketBeat recorded 12 mentions for Tourmaline Bio and 0 mentions for ERYTECH Pharma. Tourmaline Bio's average media sentiment score of 1.26 beat ERYTECH Pharma's score of 0.00 indicating that Tourmaline Bio is being referred to more favorably in the media. Company Overall Sentiment Tourmaline Bio Positive ERYTECH Pharma Neutral Does the MarketBeat Community believe in TRML or ERYP? ERYTECH Pharma received 140 more outperform votes than Tourmaline Bio when rated by MarketBeat users. However, 100.00% of users gave Tourmaline Bio an outperform vote while only 57.45% of users gave ERYTECH Pharma an outperform vote. CompanyUnderperformOutperformTourmaline BioOutperform Votes22100.00% Underperform VotesNo VotesERYTECH PharmaOutperform Votes16257.45% Underperform Votes12042.55% Is TRML or ERYP more profitable? ERYTECH Pharma's return on equity of 0.00% beat Tourmaline Bio's return on equity.Company Net Margins Return on Equity Return on Assets Tourmaline BioN/A -20.97% -20.56% ERYTECH Pharma N/A N/A N/A Do analysts rate TRML or ERYP? Tourmaline Bio currently has a consensus target price of $49.33, indicating a potential upside of 202.66%. Given Tourmaline Bio's stronger consensus rating and higher probable upside, analysts clearly believe Tourmaline Bio is more favorable than ERYTECH Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Tourmaline Bio 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 3.00ERYTECH Pharma 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryTourmaline Bio beats ERYTECH Pharma on 8 of the 14 factors compared between the two stocks. Get ERYTECH Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ERYP and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ERYP vs. The Competition Export to ExcelMetricERYTECH PharmaBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$105.77M$2.97B$5.55B$8.04BDividend YieldN/A1.87%5.09%4.22%P/E RatioN/A30.5222.6818.83Price / Sales3.24494.70404.28106.72Price / CashN/A168.6838.1834.62Price / Book3.883.216.794.33Net Income-$240,000.00-$72.35M$3.22B$247.97M ERYTECH Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ERYPERYTECH PharmaN/A$3.10flatN/AN/A$105.77M$32.66M0.0049TRMLTourmaline Bio2.7352 of 5 stars$16.48-2.2%$49.33+199.4%+13.6%$422.52MN/A-5.8344Earnings ReportNews CoveragePositive NewsSANASana Biotechnology1.9143 of 5 stars$1.73-2.0%$10.80+526.1%-80.3%$388.17MN/A-1.23380Upcoming EarningsTECXTectonic Therapeutic2.6007 of 5 stars$20.62+2.2%$72.40+251.1%N/A$383.08MN/A-3.48120Upcoming EarningsShort Interest ↑News CoverageMAZEMaze TherapeuticsN/A$8.44+0.7%$25.67+204.1%N/A$369.64M$167.50M0.00121TSHATaysha Gene Therapies1.9772 of 5 stars$1.80-0.3%$6.63+269.1%-0.4%$368.07M$8.33M2.85180News CoverageGap UpAUTLAutolus Therapeutics2.7299 of 5 stars$1.35-3.2%$9.32+592.9%-66.3%$355.24M$10.12M-1.10330Upcoming EarningsALLOAllogene Therapeutics3.3431 of 5 stars$1.58+0.3%$9.29+489.8%-42.1%$342.19M$22,000.00-1.01310Positive NewsPROKProKidney2.2851 of 5 stars$1.05+1.5%$5.00+378.5%-60.5%$305.87M$76,000.00-1.903Upcoming EarningsGap UpGLUEMonte Rosa Therapeutics1.9705 of 5 stars$4.90-1.1%$15.50+216.6%-17.5%$300.91M$75.62M-2.6790Upcoming EarningsShort Interest ↑News CoverageATYRAtyr PHARMA2.5822 of 5 stars$3.34+2.0%$18.60+457.7%N/A$295.46M$235,000.00-3.5453Short Interest ↑Analyst RevisionNews Coverage Related Companies and Tools Related Companies TRML Alternatives SANA Alternatives TECX Alternatives MAZE Alternatives TSHA Alternatives AUTL Alternatives ALLO Alternatives PROK Alternatives GLUE Alternatives ATYR Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ERYP) was last updated on 5/2/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredTrump Orders 'National Digital Asset Stockpile'Billionaires Rush Into Digital Banking Token Three massive forces are converging right now, creating what c...Crypto 101 Media | SponsoredElon’s Terrifying Warning Forces Trump To Take ActionElon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ERYTECH Pharma S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share ERYTECH Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ERYP Stock Free ERYP Stock Alerts